Pharmaceutical Drug Analysis l Report Store l Pharma Intelligence

Betaseron

Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon).

November 24, 2017

Find out more

Vertex triple combinations

Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound

September 3, 2018

Find out more

MT-2271

MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs.

January 14, 2019

Find out more

Venetoclax

Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed

for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).

September 11, 2015

Find out more

Nesina

Nesina (alogliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

November 7, 2017

Find out more

PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,

December 22, 2016

Find out more

Imlygic

Imlygic (talimogene laherparepvec; Amgen) is a gene-deleted oncolytic herpes simplex virus-1 (HSV-1) that encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF). Upon administration, Imlygic replicates selectively in tumor cells and generates GM-CSF.

May 23, 2018

Find out more

Cimzia

Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.

July 31, 2018

Find out more

Adcirca

Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).

October 29, 2018

Find out more

Semaglutide (Oral)

Novo Nordisk’s semaglutide is an orally available GLP-1 agonist currently being investigated in Phase
III trials for the treatment of type 2 diabetes. GLP-1 agonists are incretin mimetics, mimicking the
endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.

June 23, 2016

Find out more

Remicade

Remicade (infliximab; Johnson & Johnson/Merck & Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use in a number of immune-mediated inflammatory diseases, including Crohn’s disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Behçet’s syndrome, and ulcerative colitis.

August 2, 2018

Find out more

Eloctate

Eloctate (Sanofi/Bioverativ) is a fusion protein consisting of a B-domain deleted factor VIII (fVIII) protein fused to the dimeric human Fc region of immunoglobulin G-1.

May 4, 2018

Find out more

PF-06482077

Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.

December 21, 2018

Find out more